Carmenta Bioscience Secures Over $2 Million in Oversubscribed Seed Financing

Published: Aug 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has secured over $2M in seed funding. Proceeds from the financing will support development and commercialization of a new, proprietary test to better diagnose and predict preeclampsia in pregnant women. The test is based on a worldwide, exclusive technology license from Stanford University. Arising in 5-8% of pregnant mothers, preeclampsia is a leading cause of both preterm birth and maternal and fetal death.

Help employers find you! Check out all the jobs and post your resume.

Back to news